Pancreatic NET clinical trials at UCSF

1 research study open to eligible people

Pancreatic NETs are tumors in the pancreas that affect hormone-producing cells. UCSF is examining if a new drug, RYZ101, is better than standard therapies for tumors that have progressed despite prior treatments. The study looks at the drug's safety and how the body processes it.

Showing trials for

  • RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    open to eligible people ages 18 years and up

    This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.

    San Francisco, California and other locations

Last updated: